National workshop highlights pharmaceutical pollution in the Baltic Sea

Why a workshop on pharmaceutical residues in the Baltic Sea?
The Baltic Sea's marine environments contain sensitive ecosystems that are affected by the thousands of drugs prescribed across the region. We need to strengthen our knowledge of both the impacts and the trends associated with pharmaceutical pollution, while also becoming better at sharing successful interventions that address this challenge. In autumn 2025, we launched a joint project involving partners in several Baltic Sea countries. We are now beginning to gain a clearer overview of the measures being implemented across the region.

What is on the agenda for the meeting on 17 June?
This spring, we conducted a survey focusing on implemented interventions, perceived barriers, and requested incentives for reducing the environmental impact of pharmaceuticals. The response has been very positive, with results providing valuable insights into both what is already being achieved and what is needed to take further steps in the right direction. In June, we will bring together representatives from a range of organisations to validate the findings and ensure that we have captured the full picture.

What preliminary conclusions can you draw from the responses received?
That many regions and stakeholders are working successfully on several fronts, ranging from preventive health initiatives and guidance for prescribers to well-developed systems for drug disposal and wastewater treatment. Although Sweden is often regarded as a frontrunner in this important field, much remains for us to do and to learn from other countries. In September, we will therefore gather representatives from all nations participating in our research project for a joint workshop in Uppsala. Together, we will identify a common way forward based on the results of the national surveys and stakeholder meetings.

Why will you succeed in these efforts?
Bringing together expertise from the entire One Health spectrum, including both veterinary and human healthcare, strengthens our ability to address the issue effectively. We also see that the environmental impact of drugs is rising on the agendas of the United Nations and WHO as part of the broader sustainability agenda. Still, meaningful progress requires sustained and strategic efforts. After mapping initiatives and resources, our next step is to identify which successful approaches can be scaled up and adapted to maximise their benefits in each participating country. If we succeed in this, we are convinced that positive change is within reach.

text: Magnus Alsne, photo: Mikael Wallerstedt a o